Lori Call
Family · Springfield, MONPI 1043681265
Payments from drug & device makers
Across 63 payments — averaging $34.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$733
- Amgen$424
- Sanofi$228
- Boehringer Ingelheim$124
- Inari Medical, Inc.$113
- GSK$106
- plus $415 from 10 others
What the payments were for
- Food & beverage$2,10898%
- Education$342%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $733 |
| Amgen | 8 | $424 |
| Sanofi | 5 | $228 |
| Boehringer Ingelheim | 5 | $124 |
| Inari Medical, Inc. | 1 | $113 |
| GSK | 6 | $106 |
| Grifols USA, LLC | 4 | $83 |
| Insmed, Inc. | 3 | $74 |
| Regeneron Healthcare Solutions, Inc. | 4 | $72 |
| Actelion Pharmaceuticals US, Inc. | 2 | $46 |
| United Therapeutics Corporation | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Electromed, Inc. | 2 | $27 |
| Viatris Specialty LLC | 1 | $20 |
| Philips North America LLC | 1 | $19 |
| Mylan Specialty L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$246
- FASENRA$122
- DUPIXENT$118
- FLOWTRIEVER CATHETER, S$113
- CT THROMBECTOMY SYSTEM KIT$113
How this compares
$2,142 in reported general payments places this provider in the 80th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 542 | $421,111 |
| Fasenra PenBenralizumab | 31 | $171,146 |
| OfevNintedanib Esylate | 12 | $158,827 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 121 | $96,937 |
| Spiriva RespimatTiotropium Bromide | 150 | $96,232 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 137 | $67,475 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 99 | $55,613 |
| Breo ElliptaFluticasone/Vilanterol | 98 | $45,162 |
| Spiriva HandihalerTiotropium Bromide | 45 | $30,436 |
| SymbicortBudesonide/Formoterol Fumarate | 92 | $27,749 |
| Incruse ElliptaUmeclidinium Bromide | 73 | $24,740 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 41 | $17,340 |
| Advair HfaFluticasone Propion/Salmeterol | 32 | $17,304 |
| Roflumilast | 142 | $10,392 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 71 | $8,754 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $106 | $561,043863 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $124 | $310,672261 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $733 | $142,026254 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,812 family providers in Missouri.
Other family in Springfield
- Laura HedigerSpringfield$71K
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.